TB-500 Dosing: Schedule, Frequency, and Cycle Strategy

Two researchers can run the exact same TB-500 dose and end up with very different observations. The difference usually isn't the milligrams. It's the rhythm: how often, how long the cycle runs, when in the week the injections land, and what actually triggers an adjustment.

That's the part of TB-500 protocols most guides skip. The mg numbers and reconstitution math live in the TB-500 dosage guide. This guide covers the schedule itself: the structure researchers wrap around those numbers when they actually run a cycle.

Quick framing first. There's no FDA-approved TB-500 protocol. Every schedule below is research convention, extrapolated from rodent studies and the closest published human trial (which used the parent molecule, not the TB-500 fragment). All of this is published for research purposes only.

How often should you dose TB-500?

Most researchers dose TB-500 twice a week. Two subcutaneous injections, spaced roughly three to four days apart, is the rhythm published protocols and practitioner sources converge on.

That convention comes from two places. First, the rodent literature: animal studies of full-length thymosin β4 commonly dosed every three days across cardiac and stroke repair models. Second, the one published human pharmacokinetic study of thymosin β4 showed the molecule has a short stay in the bloodstream.

TB-500 drops to half its peak level within one to two hours after injection.

Here's what the human PK study actually found. In a phase I IV dosing trial of recombinant full-length thymosin β4, the half-life ranged from 0.5 to 2.08 hours. In plain English: half the dose was already gone within an hour or two.

Half-life is how long it takes your body to clear half of a single dose from your bloodstream. A short half-life doesn't mean a peptide stops working that fast (the downstream signalling can persist much longer). It does mean the peptide itself isn't sitting around for days waiting to act.

Twice weekly, spaced three to four days apart, is what most researchers actually do.

Two caveats matter here:

• That PK study used IV full-length thymosin β4, not subcutaneous TB-500 (the seven-amino-acid fragment). No published PK study of the TB-500 fragment itself exists in humans.
• Subcutaneous injection releases peptides more slowly than IV, so real systemic exposure from a SC TB-500 dose probably lasts longer than the IV figure suggests. How much longer isn't documented.

So the once-versus-twice-weekly question is essentially: do you keep the signalling cascade nudged twice a week, or do you let it run on a single weekly pulse? Most researchers go twice weekly. A minority run once weekly during maintenance phases, on the rationale that downstream repair signalling persists past the peptide's own clearance.

Loading vs maintenance: what's the real difference?

The "loading then maintenance" pattern shows up everywhere in TB-500 community protocols. It's worth being honest about where it actually came from.

Loading means a higher-frequency or higher-dose phase at the start of a cycle, typically 4 to 6 weeks. Maintenance means a lower-intensity phase after that, sometimes a different cycle entirely, sometimes a tapered continuation. The idea is to push the system harder early, then drop to a sustaining rhythm.

Loading phase uses higher weekly doses for four to six weeks, then drops to lower maintenance doses.

The structure has a real precedent, just not the one most guides claim. The closest published human regimen for any thymosin β4 molecule is the RGN-352 acute myocardial infarction trial protocol (NCT01311518, sponsored by RegeneRx Biopharmaceuticals). That registered protocol used three consecutive daily IV bolus doses, then weekly for four more weeks (seven doses total). The trial itself was withdrawn before enrollment, but the protocol design is the closest real-world anchor a loading-then-weekly pattern has for any thymosin β4 molecule.

The four-to-six-week loading then lower-dose maintenance convention quoted in community protocols isn't from a published TB-500 paper. It's extrapolated from RGN-352 plus the every-three-days pattern in rodent dosing schedules.

What the loading phase typically looks like in practice:

• 5 to 10 mg per week, split into two SC injections
• Four to six weeks duration
• Highest typical intensity in a given research cycle
• Often used in acute injury or fresh-protocol windows

What maintenance typically looks like:

• 2 to 5 mg per week, often as a single weekly injection
• Used after a loading window, or as a standalone lower-intensity research cycle
• Sometimes paused entirely with the planned off period substituting for maintenance

If you want the underlying mg math (where the 5-to-10 mg figure comes from), the TB-500 dosage guide covers the interspecies scaling. This section is about the structure, not the math.

How long should a TB-500 cycle actually run?

Cycle length is one of the more debated parts of TB-500 protocol design.

The community convention is a 4-to-8-week active phase, followed by a 2-to-4-week off period. Some researchers stretch the active phase to 12 weeks for chronic-application research; some compress it to 4 weeks for short tissue-repair windows.

Three common TB-500 cycle structures, each alternating active and off phases to establish a measurable baseline.

The rationale for taking breaks isn't a documented receptor desensitisation finding. It's two practical things: first, breaks give you a clean baseline to assess what changed; second, the published animal work that informs TB-500 dosing is itself episodic, not continuous, so continuous use moves beyond what the literature actually maps.

Typical cycle structures researchers describe:

Cycle type	Active phase	Off period	Common use
Acute / loading	4–6 weeks	2–4 weeks	Fresh tissue research, injury models
Standard	6–8 weeks	3–4 weeks	General recovery research
Extended	8–12 weeks	4–6 weeks	Chronic-application research

The pattern across all three: there's always an off period.

Many users report that the cleanest read on TB-500 effects comes in week three or four of an active cycle, with the sharpest comparison after a two-week off period returns to baseline. That's the practical case for the break itself: a structured off period is what gives the next cycle something to be compared against.

When during the week should you dose?

Spacing matters more than the specific calendar day.

The classic Monday/Thursday or Tuesday/Friday split puts roughly three days between injections, which lines up with the rodent every-three-days dosing pattern in published cardiac and stroke models. Some researchers shift to Sunday/Wednesday for the same spacing. None of these are validated as superior. The principle is consistent spacing.

The training-timing question comes up a lot. Research suggests tissue repair signalling is most relevant after stress, not before, so most researchers default to dosing the same day as (or the day after) their hardest training session rather than the morning of a workout. There's no human data confirming this matters either way. It's a logic-driven convention.

What about time of day? Subcutaneous TB-500 absorbs over hours, so morning-versus-evening is mostly down to consistency. Pick a slot you'll actually hit reliably.

Common schedule patterns:

• Mon AM / Thu AM: twice-weekly classic
• Tue PM / Fri PM: evening dosing for researchers tracking sleep recovery
• Sat PM / Wed PM: weekend-anchored to align with peak training days
• Sun PM only: once-weekly maintenance variant

The bigger point: pick a schedule and hold it for the full cycle. Inconsistent days defeat the steady-state thinking the schedule is meant to support.

How do researchers decide when to adjust?

This is where TB-500 protocols get less precise than people expect.

There's no validated blood marker for TB-500 status. You can't draw a panel and see whether you're under-dosed or over-dosed. So researchers track subjective signals, the same signals they'd track in any structured recovery research log: joint comfort, soft-tissue recovery time between sessions, sleep quality, and the specific tissue concern that prompted the cycle in the first place.

Common signals researchers describe as triggers to adjust:

• Faster recovery between training sessions by week 3–4: maintain current dose, plan the off period
• No observable change by end of week 4: reassess delivery route or sourcing before raising the dose
• Sleep disruption or persistent injection-site sensitivity: reduce dose or shift to a single weekly injection
• Early plateau after a strong week-2 response: consider taking the planned break early rather than raising mg

In our protocol design work at Peak Human Labs, when we map TB-500 research cycles for participants, the dose itself is usually the last variable we touch. We adjust the schedule and route first, because the published literature gives us much less to anchor on for the upper end of dosing than for the lower end. Going higher without changing anything else rarely produces a cleaner read; it just moves further from documented research ranges.

If a cycle isn't producing observable change by week 4, the more useful question isn't "should I increase the dose," it's "is the delivery route doing what I assumed it was doing." That's the case where considering a validated sublingual route, such as VERO's RESTORE protocol, gives you a cleaner second cycle to compare against.

Does TB-500 dosing change for different research applications?

It does, and the published animal literature is clearer here than on most TB-500 dosing questions.

Acute injury research uses concentrated schedules. A 2012 traumatic brain injury rat study dosed three times in the first 48 hours, starting six hours after injury, then again at 24 and 48 hours. A 2014 stroke dose-response study dosed once 24 hours after the stroke event, then every three days for four more doses. A 2013 cardiac ischemia study dosed daily for the first three days, then every third day out to 28 days.

How TB-500 dosing frequency shifts from acute injury response to long-term maintenance.

The pattern across all three: high-frequency dosing immediately after the acute event, tapering to every-three-days. That's the closest the literature gets to a "loading" rationale, and it's specific to the acute-injury model.

Maintenance-style or longevity-style research uses lower frequency. Once or twice weekly, with the cycle running longer. The rationale is different: the goal is to support tissue maintenance across a structured window, rather than respond to a fresh event.

Research context	Typical dosing rhythm	Cycle length
Acute injury models (animal)	Daily for 2–3 days, then every 3 days	2–4 weeks total
General tissue-repair research	Twice weekly	4–8 weeks
Maintenance / longevity-style	Once weekly	8–12 weeks

Rule of thumb: the more acute the research application, the more frequent the dose and the shorter the cycle.

The most common TB-500 dosing mistakes

After enough protocol-design conversations, the same handful of mistakes shows up over and over.

1. Skipping the break. Running continuous cycles back to back without an off period eliminates the comparison baseline that makes adjustment possible. Continuous use also moves beyond what the published animal protocols actually tested.
2. Changing route mid-cycle. Switching from subcutaneous to sublingual to oral capsule inside a single cycle changes systemic exposure mid-comparison. If you're testing a new route, run a full cycle on it before drawing any comparison.
3. Stacking confusion. Co-administering TB-500 and BPC-157 in the same hour, without spacing them, makes it harder to attribute any observation to either peptide. Most researchers space them by hours, sometimes by days.
4. Front-loading expectations. TB-500's downstream signalling takes time. Researchers typically don't report observable change until week 2 or 3 of an active cycle, sometimes later.
5. Inconsistent days. Dosing Mon/Thu one week and Tue/Sat the next defeats the steady-state thinking the schedule is meant to support.
6. Forgetting WADA status. TB-500 sits on the WADA Prohibited List under S2 (peptide hormones, growth factors, related substances), banned both in and out of competition. Tested athletes shouldn't be running TB-500 cycles at all.

Can you dose TB-500 alongside BPC-157?

This is one of the most common stacking questions in the recovery-research community.

No published interaction studies between TB-500 and BPC-157 exist in humans. What exists is community observation that the two peptides act on different signalling pathways. BPC-157 has been characterised in animal studies as affecting gut and connective-tissue signalling; TB-500's mechanism has been described in research reviews as actin sequestration with downstream tissue-repair effects.

Two common stacking schedules: daily BPC-157 with twice-weekly TB-500, or both peptides for 4–6 weeks followed by BPC-157 maintenance.

Two common stacking schedules researchers describe:

• Daily BPC-157 with twice-weekly TB-500. BPC-157 in the morning (sublingual or SC), TB-500 dosed Mon/Thu in the evening. Spacing them by hours rather than co-administering.
• Loading-phase combined cycle. Both peptides for the first 4–6 weeks of a fresh recovery research window, then continuing BPC-157 maintenance alone after the TB-500 cycle ends.

If you're new to either peptide, the cleaner approach is to run them sequentially first (one full cycle of each) to develop a baseline for what each contributes. Stacking from day one without that baseline makes attribution difficult.

For BPC-157 dosing math and route comparison, see the BPC-157 dose guide. For the TB-500 mg ranges, see the TB-500 dosage guide. This section is about how the two schedules interact, not how to size either dose.

RESTORE: Where TB-500 dosing fits the VERO protocol stack

VERO members experience tissue-repair research differently than most TB-500 protocols set up: as a structured cycle inside a broader recovery stack, not as a standalone peptide running on its own.

The RESTORE Protocol sits in the tissue-repair family of VERO peptides. It anchors on BPC-157 delivered sublingually via VERISORB Quicksome™ technology (which bypasses GI degradation), with structural room to add TB-500 for cycles where active repair signalling is the focus of the research window.

What that looks like in practice:

• BPC-157 dosed daily sublingually across the full cycle
• TB-500 added for a 4–6 week loading window when the application calls for it
• Off period built into the protocol calendar, not skipped
• Pharmaceutical-grade sourcing, third-party tested

The structure matters more than the peptide count. Most TB-500 dosing problems are schedule problems, not dose problems, and getting the rhythm, the combination, and the off period right is where structured protocols win.

All VERO protocols are for research purposes only.

Frequently Asked Questions

What's the most common TB-500 dosing frequency?

Twice weekly, spaced three to four days apart. Two subcutaneous injections at 2.5 to 5 mg each is the most-cited research convention, drawn from rodent every-three-days dosing patterns and from the loading-then-weekly structure of the only human thymosin β4 trial on record.

Should I dose TB-500 daily?

Not under the standard convention. Published animal models for chronic or maintenance research don't dose daily, and the only human-trial precedent for any thymosin β4 molecule uses three daily doses only as an acute IV loading window, then drops to weekly. Daily dosing without that acute-trigger context moves beyond what the literature actually maps.

How long does a TB-500 cycle typically last?

4 to 8 weeks for an active phase, followed by 2 to 4 weeks off. Acute or loading cycles can compress to 4 weeks; extended research cycles can stretch to 12 weeks. The off period isn't optional under standard protocols. It's the baseline reset that makes the next cycle interpretable.

Can you cycle TB-500 indefinitely?

Not within the published research framework. No animal protocol tested continuous dosing past the cycle structures described in the literature, so continuous use moves outside what the evidence actually covers. Most researchers cap at two to three cycles per year.

Does timing relative to training matter?

Probably not as much as consistency does. Research suggests repair signalling is most relevant after tissue stress rather than before, so most researchers dose the same day as (or the day after) their hardest training session, not pre-workout. There's no human data confirming this matters; it's logic-driven, not evidence-driven.

Is TB-500 banned in sport?

Yes. TB-500 has been on the WADA Prohibited List under S2 (peptide hormones, growth factors, related substances) since the USADA athlete advisory listed it explicitly in 2018. It is banned both in and out of competition.

Key Takeaways

• Most TB-500 dosing problems are schedule problems, not dose problems. Frequency, cycle length, and consistency typically matter more than the exact milligrams.
• Twice-weekly subcutaneous dosing, spaced three to four days apart, is the standard research convention. It comes from rodent every-three-days dosing patterns and the loading-then-weekly structure of the only human thymosin β4 clinical trial.
• The "loading then maintenance" framing is community convention, not a published TB-500 protocol. The closest real anchor is the RGN-352 acute MI trial protocol (NCT01311518, withdrawn before enrollment), which specified three daily IV loading doses then weekly for four weeks.
• Cycles typically run 4–8 weeks active, 2–4 weeks off. Continuous dosing isn't supported by any published animal protocol.
• Adjustment usually means changing the schedule or route, not the dose. There's no validated blood marker for TB-500 status, so researchers track subjective signals over weeks.
• Acute-injury animal research uses concentrated dosing (daily for 2–3 days, then every 3 days). Maintenance research uses lower frequency. The application shapes the schedule.
• TB-500 is WADA-banned under S2 (peptide hormones and growth factors), in and out of competition. Tested athletes shouldn't run TB-500 cycles.
• Common dosing mistakes: skipping the break, changing route mid-cycle, stacking without spacing, front-loading expectations, inconsistent days, and forgetting WADA status.

References

• Wei C, et al. Phase I pharmacokinetics of recombinant human thymosin β4 in healthy volunteers (first-in-human PK study). Clinical and Translational Science. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8419156/. Retrieved 2026-06-05.
• U.S. FDA, Center for Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. July 2005. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. Retrieved 2026-06-05.
• U.S. Anti-Doping Agency. 2018 Prohibited List: summary of major changes (TB-500 listed under S2.3 growth factors). October 2017. https://www.usada.org/athlete-advisory/2018-prohibited-list-summary-of-major-changes/. Retrieved 2026-06-05.
• World Anti-Doping Agency. 2026 Prohibited List. September 2025. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf. Retrieved 2026-06-05.
• RegeneRx Biopharmaceuticals. RGN-352 IV thymosin beta 4 dosing regimen in acute myocardial infarction (trial protocol summary, NCT01311518). ClinicalTrials.gov. 2019. https://clinicaltrials.gov/study/NCT01311518. Retrieved 2026-06-05.
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4 as an actin-sequestering protein in tissue-repair signalling (mechanism review). Trends in Molecular Medicine. 2005. https://pubmed.ncbi.nlm.nih.gov/16099219/. Retrieved 2026-06-05.
• Philp D, Kleinman HK. Animal studies of thymosin β4 in tissue repair and regeneration (review). Annals of the New York Academy of Sciences. 2010. https://pubmed.ncbi.nlm.nih.gov/20536453/. Retrieved 2026-06-05.
• Morris DC, et al. Thymosin β4 dose-response in a rodent embolic stroke model (every-three-days IP dosing schedule). 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC4177939/. Retrieved 2026-06-05.
• Xiong Y, et al. Thymosin β4 dosing schedule in a rat traumatic brain injury model (daily IP for three days). 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3392183/. Retrieved 2026-06-05.
• Systemic thymosin β4 dosing in a rat myocardial ischemia model (daily-then-every-three-days IP schedule). 2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843122/. Retrieved 2026-06-05.

---

Ready to structure a TB-500 research cycle inside a proper recovery stack? Explore RESTORE →